Review Assesses Pharmacotherapies for Adult ADHD
The review included a total of 81 unique trials that reported 1 or more outcomes of interest.
Attention-Deficit/Hyperactivity Disorder
FDA Clears Video Game-Based Therapy for Pediatric ADHD
The FDA has cleared EndeavorRxTM (AKL-T01; Akili Interactive) for use as a prescription-only video game-based digital therapeutic to improve attention function in pediatric patients aged 8-12 years with primarily inattentive or combined-type ADHD.
Triple Reuptake Inhibitor Centanafadine Looks Promising for Adult ADHD
Centanafadine is a serotonin-norepinephrine-dopamine reuptake inhibitor. The two, 6-week, multicenter, double-blind, placebo-controlled trials (Study 1 and Study 2) evaluated the efficacy and safety of centanafadine sustained-release tablets in approximately 900 adult patients with ADHD.
FDA to Review Manipulation-Resistant Stimulant Med for ADHD
AR19 is an investigational immediate-release, amphetamine formulated to prevent the manipulation of the pellets in the capsules for nonmedical use.
Dasotraline Development for ADHD, Binge Eating Disorder Halted, NDAs Withdrawn
n August 2018, the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) stating the application required additional data to further assess the efficacy and tolerability of dasotraline.
FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Recommendations Developed for Management of Complex ADHD
Treatment should include evidence-based approaches and account for coexisting conditions.
Viloxazine NDA Submitted for Review as Potential New ADHD Treatment
The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD). The submission is supported by data from an extensive development program that included four phase 3 studies…
Concomitant Stimulant, Quinolone Use May Increase Risk of Cardiac Symptoms
There appears to be an increased risk of cardiac symptoms, but not cardiac arrhythmias, in patients using stimulants and quinolone antibiotics concomitantly compared with those taking stimulants plus amoxicillin or azithromycin, according to the findings of a recently published retrospective cohort study. In the study, MarketScan claims data (between 2008 and 2015) of privately-insured patients…
Fetal Exposure to Acetaminophen May Increase Risk for ADHD, ASD
Cord biomarkers of in utero acetaminophen exposure tied to increased risk for childhood ADHD, ASD.
